Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer
Small · 2023
DOI: 10.1002/smll.202207778 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small, 2023. Verfasst von Jia-Yi Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Tradi…. Hauptthemen laut MEDLINE: Nanomedicine, Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Targeted protein degradation (TPD) is an emerging therapeutic strategy with the potential of targeting undruggable pathogenic proteins. After the first proof‐of‐concept proteolysis‐targeting chimeric (PROTAC) molecule was reported, the TPD field has entered a new era. In addition to PROTAC, numerous novel TPD strategies have emerged to expand the degradation landscape. However, their physicochemical properties and uncontrolled off‐target side effects have limited their therapeutic efficacy, raising concerns regarding TPD delivery system. The combination of TPD and nanotechnology offers great promise in improving safety and therapeutic efficacy. This review provides an overview of novel TPD technologies, discusses their clinical applications, and highlights the trends and perspectives in TPD nanomedicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
- Center for Nanomedicine and Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
- Department of Chemistry and Biochemistry, College of Liberal Arts, University of Mississippi, University-1848, Boston, MA, 38677, USA.
- Department of BioMolecular Sciences and Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University-1848, Boston, MA, 38677, USA.
ORCID-Profile: Xin Luan
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Zitieren
APA
Lin, J. Y., Liu, H. J., Wu, Y., Jin, J. M., Zhou, Y. D., Zhang, H., Nagle, D. G., Chen, H. Z., Zhang, W. D., & Luan, X. (2023). Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer. Small. https://doi.org/10.1002/smll.202207778
Vancouver
Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, et al. Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer. Small. 2023. doi:10.1002/smll.202207778
BibTeX
@article{Lin2023,
author = {Lin, Jia-Yi and Liu, Hai-Jun and Wu, Ye and Jin, Jin-Mei and Zhou, Yu-Dong and Zhang, Hong and Nagle, Dale G and Chen, Hong-Zhuan and Zhang, Wei-Dong and Luan, Xin},
title = {Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202207778}
}
EUVIMED